Tin binding and reporter activity of enhancers active in dorsal mesodermal cells, cardiac progenitors and heart progenitors.

<p>(A–P) show the Tin binding peaks (blue: 3–5.5 hrs: pink: 5–8 hrs AEL), the location of the tested enhancers (yellow bars) and the gene models (red: genes closest to tested fragment). Y axes are at identical scales whereas x axis scales are variable (see scale bars). A′ to P′ show enhancer activities at earliest stage of appearance (arrow or arrow heads: dorsal/cardiac mesoderm) and A″ to P″ at latest stage of detection in cardiac tissues (arrows or arrow heads). Shown are <i>GFP</i> or <i>lacZ in situ</i> hybridizations except in A″, I′, I″ and P″, which show anti-GFP antibody stainings (in A″, I″ and P″ perduring GFP from earlier expression). Genes are ordered alphabetically, with CGs last. (A′) Stage 12. Expression of <i>discoL10-GFP</i> in heart progenitors, segmental subsets of visceral muscle precursors and (A″), stage 14, perdurance of GFP in developing visceral muscles and heart. (B′, B″) Expression of <i>EgfrE1-lacZ</i> in cardioblast progenitors and subsets of somatic mesodermal cells (stage 12), and in cardioblasts (stage 14). (C′, C″) Expression of <i>fzL4-GFP</i> in cardioblast progenitors (stage 12) and in cardioblasts and amnioserosa (stage 14). (D′, D″) Expression of <i>HimL47-GFP</i> in cardiogenic mesoderm and somatic mesodermal cells (stage 12), and in cardioblasts and developing somatic muscles (stage 14). (E′, E″) Expression of <i>hthE54-GFP</i> in heart progenitors of Md, T1–T3 segments (arrow heads) and in somatic mesoderm (with A–P graded sizes of clusters) (stage 12) and in anterior developing heart cells (arrow head) and somatic muscles (stage 14). (F′, F″) Expression of <i>lin-28L64-GFP</i> in cardioblasts (stage 12, stage14). (G′, G″) Expression of <i>maL9-GFP</i> in cardiac and somatic mesoderm (stage 12) and in heart precursors (stage 14). (H′, H″) Expression of <i>midE19-GFP</i> in Tin⁺ cardioblasts (stage 12, stage 15). (I′, I″) Expression (I′, stage 12) and perdurance (I″ stage 14) of <i>nauL35</i>-GFP largely in dorsal somatic mesoderm (asterisks). (J′, J″) Expression of <i>nocL7-GFP</i> in pericardial cell progenitors (stage 12) and pericardial cells (stage 16). (K′, K″) Expression of <i>RhoLE102-GFP</i> in segmented dorsal mesoderm (stage 11) and cardioblast progenitors (stage 12). (L′, L″) Expression of <i>tshL8-lacZ</i> in cardiogenic mesoderm and thoracic ectoderm (stage 11) and in Tin⁺ pericardial cells (stage 15). (M′, M″) Expression of <i>tupE9-GFP</i> in cardiogenic mesoderm (stage 11) and cardioblasts (stage 14). (N′, N″) Expression of <i>unc-5L25-GFP</i> in cardioblast and pericardial cell progenitors (stage 12) and in cardioblasts and Tin⁺ pericardial cell (stage 16). (O′, O″) Expression of <i>CG3638L6-GFP</i> in cardioblast progenitors (stage 12) and cardioblasts (stage 15). (P′, P″) Expression of <i>CG9973E15-GFP</i> in cardiac mesoderm (stage 11) and perdurance of GFP in developing heart (stage 14).